RE:Dr. Peter Dicpinigaitis Appointed to the Advisory Board Yes, the good doctor has world class credentials. However, the bottomline goes something like this:
When does/will the trial actually start?
In how many different countries will they complicate the matters at hand?
Romania was a hair on fire location for 75% of Algernon Pharmaceuticals' last billed "Multinational" COVID-19 clinical trial. We all remember how the fire broke out at the hospital where clinical trial records were stored. We also know any studies conducted in Australia will come with significant recruitment challenges for a small company like Algernon Pharmaceuticals. Challenges requiring unnecessary delays for management's stated reasoning to receive "Tax Rebates". Tax Rebates that trickle in well beyond the point of making any positive impact as delays only hurt stock momentum as witnessed leading to rounds and rounds of dilution and a colossal and catastrophic 100/1 reverse split. It’s without a doubt the most negatively impactful decision to date by the company among a list of others. There remains no foreseeable uplist to NASDAQ as AlphaNorth gobbles up the company through fire sale offerings.
Need Algernon Pharmaceuticals continue to travel down that same ineffective path for a 180 patient clinical trial for chronic cough?
Questions Questions…shareholders never receiving the right results or answers. Here’s a novel idea (lightbulb), why not $imply follow the $ame tried and true path as Bellus Health?
You’ve already got the world's premier expert for chronic cough on your Medical and Scientific Advisory Board - Jacky Smith, MB, ChB, FRCP, PhD. If you can rely on her to interpret and reinterpret your chronic cough data in the most favorable light, I’m guessing that’s what ultimately compelled you to no longer ignore conducting a standalone chronic cough study. Albeit the other option (IPF/CC) would likely have been catastrophic. Management has now added an EINSTEIN (Dr. Peter Dicpinigaitis) in his own right to the Medical and Scientific Advisory Board.
It's one thing to continuously rant and rave (drama) and jump up and down year over year on talk talk talk shows in pennyworld claiming you’re a pure competitor to Bellus Health and/or Merck. It's another thing to truly walk the walk.
A true measure moving forward is how will Algernon Pharmaceuticals stack up against Bellus Health's timeline of completing a Phase 2b chronic cough study in the USA within 1 year of start to finish?
Bellus Health did it without conducting a fancy pansy Multinational this or that. Lest we forget Algernon Pharmaceuticals previous Multinational clinical trial had less than 10% of all patients in the USA with Zero patients in Canada.
What, there's no available chronic cough patients/clinics in Canada?
Just keep the mission simple to avoid all the same trappings of conducting studies on the cheap like a basement bargain bin boiler operator operation. Maybe avoid the next pandemic/epidemic which shuts down entire countries like Australia that brought the last clinical trial to a screeching halt. That’s beyond management knowing about Australia’s inherently poor recruitment timelines and still going in there for “Tax Rebates”. It should have been a whammy to the Wake Up noggin (being woke isn’t all that bad after all). If you conduct the clinical trial in North America where your largest target market resides that signals you mean business. You're not once again subjecting shareholders to repeating failed strategies of a perilous past - We $eek $afe Harbor. Retail investors do not have the luxury of doling out free shares to themselves come hell or high water. Getting to DATA ASAP is the only true game in town (USA/Canada).